BioSpace News Archive

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant360 Response test.

SAB Biotherapeutics (Nasdaq: SABS), (SAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.

Ocelot Bio, Inc. today announced that Lise Kjems, M.D., has joined the organization as chief medical officer.

Simulations Plus, Inc. today announced that the U.S. FDA has renewed its licenses to the DILIsym ® software platform, the flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

Juntendo University, Sysmex Corporation, and ThinkCyte K.K. have announced a collaborative research partnership to advance the early detection and treatment of chronic myelogenous leukemia (CML).

Royal Philips, a global leader in health technology, announced the results of its Future Health Index 2023 report: Taking healthcare everywhere.

Theratechnologies Inc. today presented preclinical data that demonstrate the potential utility of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902) -- both as a single agent and in combination with other anticancer therapies -- in targeting tumors that express the sortilin (SORT1) receptor.

Erasca, Inc. (Nasdaq: ERAS) today presented promising initial Phase 1b dose escalation data from FLAGSHP-1 for ERAS-601 in combination with cetuximab (ERBITUX®) in patients with advanced solid tumors as part of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Notable Labs, Inc. (“Notable”) today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open of the U.S. financial markets.